| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular DysfunctionNCT04614467 | LSTA | Phase 2 | Terminated | 2022-09-28Actual |
| Study of Exchange of Travoprost Intraocular ImplantNCT04615403 | Glaukos Corporation | Phase 2 | Completed | 2022-02-28Actual |
| Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk FactorsNCT04615949 | CRDL | Phase 2, Phase 3 | Terminated | 2022-11-30Actual |
| RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex DiseaseNCT04616924 | RedHill Biopharma Limited | Phase 3 | Terminated | 2023-08-28Actual |
| Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene FusionNCT04617054 | NUVB | Phase 2 | Terminated | 2024-12-06Actual |
| A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung CancerNCT04620330 | VSTM | Phase 2 | Completed | 2023-08-29Actual |
| Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular AllergiesNCT04622345 | Vanda Pharmaceuticals | Phase 2 | Completed | 2021-05-22Actual |
| A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS MutationNCT04625270 | VSTM | Phase 2 | Active not recruiting | 2024-11-15Actual |
| Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 SubjectsNCT04629703 | Rigel Pharmaceuticals | Phase 3 | Completed | 2022-09-05Actual |
| Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMDNCT04632940 | Kyntra Bio | Phase 3 | Terminated | 2023-06-12Actual |
| A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibNCT04633122 | Zai Lab (Shanghai) Co., Ltd. | Phase 2 | Completed | 2022-07-20Actual |
| Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory TractNCT04633187 | ENTA | Phase 2 | Terminated | 2023-05-31Actual |
| Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)NCT04634669 | AXSM | Phase 2 | Terminated | 2022-02-18Actual |
| Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck CancerNCT04634825 | MacroGenics | Phase 2 | Terminated | 2022-07-29Actual |
| Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the KneeNCT04636229 | Organogenesis | Phase 3 | Completed | 2023-07-30Actual |
| XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic EncephalopathyNCT04639310 | XENE | Phase 3 | Terminated | 2023-05-16Actual |
| Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 ExposureNCT04642638 | Inovio Pharmaceuticals | Phase 2, Phase 3 | Terminated | 2022-09-13Actual |
| Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)NCT04652882 | Vanda Pharmaceuticals | Phase 3 | Completed | 2026-09-04Actual |
| Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)NCT04655313 | ARQT | Phase 2 | Completed | 2022-01-12Actual |
| A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic AtrophyNCT04656561 | ANNX | Phase 2 | Completed | 2023-03-28Actual |
| Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple SclerosisNCT04657666 | Jazz Pharmaceuticals | Phase 3 | Completed | 2022-05-04Actual |
| A Study of Auxora in Patients With Critical COVID-19 PneumoniaNCT04661540 | CALC | Phase 2 | Terminated | 2021-12-21Actual |
| Efficacy and Safety of LX9211 in Participants With Postherpetic NeuralgiaNCT04662281 | Lexicon Pharmaceuticals | Phase 2 | Completed | 2022-11-18Actual |
| A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)NCT04663308 | MIRM | Phase 2 | Active not recruiting | 2026-02-20Actual |
| A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy AdultsNCT04668339 | Arcturus Therapeutics, Inc. | Phase 2 | Terminated | 2022-03-01Actual |
| A Phase 3 Study of NE3107 in Probable Alzheimer's DiseaseNCT04669028 | BIVI | Phase 3 | Completed | 2023-09-30Actual |
| The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye DiseaseNCT04674358 | ALDX | Phase 2, Phase 3 | Completed | 2021-09-12Actual |
| Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)NCT04675294 | ALX Oncology Inc. | Phase 2 | Active not recruiting | 2025-03-03Actual |
| Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)NCT04675333 | ALX Oncology Inc. | Phase 2 | Active not recruiting | 2025-03-03Actual |
| A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)NCT04677179 | NKTR | Phase 2 | Terminated | 2022-08-09Actual |
Trial details
- Registry ID
- NCT04614467
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04615403
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04615949
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04616924
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04617054
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04620330
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04622345
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04625270
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04629703
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04632940
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04633122
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04633187
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04634669
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04634825
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04636229
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04639310
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04642638
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04652882
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04655313
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04656561
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04657666
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04661540
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04662281
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04663308
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04668339
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04669028
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04674358
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04675294
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04675333
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04677179
- Phase
- Phase 2
Primary completion marks the end of data collection for the main study measures, not a results publication date.